Sustanon 270
Sustanon 270 Dragon Pharma
Testosterone Blend 270 mg/mL · 4-Ester Injectable · high aromatization
Class
Testosterone
Injectable AAS
Ester / Active Life
4-Ester Blend
~2–18 days (prop → dec)
Aromatization
High
AI required from day 1
User Level
Intermediate
to Advanced
Typical Dose
270–540 mg
per week
Injection Frequency
2×/week
twice weekly
Cycle Length
10–16 weeks
typical range
Lab Tested
$55.00
$55.00
In Stock
Shipping
Sustanon 270 Dragon Pharma — Overview
Sustanon 270 Dragon Pharma is a four-ester testosterone blend formulated at 270 mg/mL — built on the principle of fast onset through short esters and sustained release through long esters in a single injection. Each milliliter contains testosterone propionate (30 mg), testosterone phenylpropionate (60 mg), testosterone isocaproate (60 mg), and testosterone decanoate (120 mg). This architecture was designed to front-load a testosterone peak within the first 24–72 hours of the initial dose while maintaining elevated levels across the full week without requiring the injection frequency of a short-ester-only protocol.
At 270 mg/mL, Dragon Pharma's blend carries 8% more testosterone per milliliter than the standard 250 mg/mL formulations — a meaningful difference when calculating weekly dose volumes. A single 10 mL vial provides 2,700 mg of total testosterone, covering a 10-week cycle at 270 mg/week or a 5-week phase at 540 mg/week. steroidwarehouse.com carries Sustanon 270 alongside Dragon Pharma's full injectable lineup and the complete cycle support range needed to run it correctly.
Testosterone Blend 270 mg/mL 4-Ester Injectable Prop / PP / Isocap / Dec Mass & Strength Intermediate – Advanced
On this page
About the Compound: 4-Ester Testosterone Blend
The four esters in Sustanon 270 cover distinct segments of the pharmacokinetic curve. Testosterone propionate (30 mg, ~2–3 day half-life) produces the initial peak. Phenylpropionate (60 mg, ~4–5 days) and isocaproate (60 mg, ~7–9 days) extend active levels through the mid-week window. Decanoate (120 mg, ~14–16 day half-life) accounts for 44% of the total dose and sustains testosterone release for 3+ weeks after each injection — the fraction that most shapes clearance time and PCT strategy. At twice-weekly injections, these four esters overlap to produce a profile with an early peak and sustained plateau throughout each 3–4 day interval.
- Rapid onset from the propionate fraction — testosterone propionate begins releasing within hours of injection; a clinically significant testosterone peak arrives within 24–72 hours of the first dose; this gives Sustanon a measurably faster performance onset than enanthate or cypionate, where 3–4 weeks are typically needed to reach steady state
- Sustained release from the decanoate fraction — at 120 mg per mL, testosterone decanoate is the dominant ester by weight and half-life; it sustains measurable testosterone release for up to 3 weeks after the last injection; this is the critical factor that delays PCT entry relative to all single-ester testosterone formats and requires a 21-day washout before SERMs begin
- High aromatization — testosterone aromatizes readily to estradiol via aromatase; all four esters deliver the same hormone and contribute to the same cumulative aromatization burden; the propionate fraction creates an early E2 rise in the first week that appears faster than with enanthate-only protocols; AI management is mandatory from injection day one
- 5α-Reductase conversion to DHT — testosterone is converted to dihydrotestosterone in androgen-sensitive tissues (scalp, skin, prostate) via 5α-reductase; DHT drives androgenic side effects including acne, oily skin, and androgenic alopecia in predisposed users; finasteride reduces DHT at the scalp and prostate without affecting any non-testosterone AAS co-administered in a stack
- Complex but manageable pharmacokinetics — the four half-lives produce a release curve that is less predictable than a single-ester testosterone; AI dose-finding requires a week-3 E2 check because the early propionate peak and later steady-state from decanoate create different E2 loads at different points in the cycle; bloodwork-guided adjustment is more important here than with Enantat 250 or Cypionat 250
Active Substance
4-Ester Testosterone Blend
Concentration
270 mg/mL · 10 mL vial
Ester Profile
Prop 30 / PP 60 / Isocap 60 / Dec 120 mg
Half-life Range
~2 days (prop) → ~16 days (dec)
Aromatization
High — AI required
5α-Reduction
Yes → DHT
Hepatotoxicity
None
PCT Start
21 days after last injection
Pack yields
2,700 mg — 10 wk at 270 mg/wk
What Sustanon 270 Does
Testosterone is the primary endogenous androgen in males and acts through high-affinity binding to the androgen receptor (AR) — a nuclear receptor that drives transcription of genes governing skeletal muscle protein synthesis, nitrogen retention, IGF-1 secretion, and erythropoiesis. Sustanon 270 delivers testosterone through four esters that stagger the release curve, but the anabolic mechanism is identical to any other testosterone form at the same total weekly dose.
- Lean mass and strength gains — supraphysiologic testosterone increases muscle fiber cross-sectional area via AR-mediated protein synthesis, reduces catabolic glucocorticoid activity, and raises IGF-1; in a 10–16 week cycle at 400–540 mg/week users consistently achieve meaningful increases in lean mass and training performance; the multi-ester profile does not change the anabolic output per milligram compared to enanthate or cypionate
- Faster early cycle performance vs long esters — the propionate fraction produces a testosterone peak within 72 hours of the first injection; performance improvements and muscle fullness are typically noticeable in week 1–2, before a single-ester enanthate cycle reaches steady state; this is the most clinically relevant advantage of the multi-ester format for users who do not want to use a separate oral kickstart
- Estrogenic muscle fullness and glycogen storage — aromatization to estradiol at supraphysiologic testosterone doses increases intramuscular glycogen storage, muscle volume, and connective tissue hydration; the scale weight gains on a testosterone cycle are partly E2-mediated and explain why gains partly reverse if E2 is over-suppressed or post-cycle water is lost; these effects are dose-dependent and AI management keeps E2 in the productive range
- Erythropoiesis — red blood cell and hematocrit increase — testosterone stimulates EPO production in the kidneys, progressively increasing red blood cell mass and hematocrit throughout the cycle; on 10–16 week cycles this effect accumulates meaningfully; hematocrit above 52% increases blood viscosity and cardiovascular risk and requires intervention
- HPG axis suppression — endogenous LH and FSH drop to near-zero within the first weeks via androgen-mediated negative feedback; testicular testosterone production ceases; testicular atrophy proportional to cycle duration occurs without HCG support; structured PCT after the decanoate ester clears is required to restart the axis; the multi-ester profile means suppression persists for approximately 3 weeks after the last injection before testosterone levels begin dropping toward the PCT-entry threshold
Who It's For
- What sets Sustanon 270 apart: among Dragon Pharma's injectable testosterone products, Sustanon 270 is the only 4-ester blend — all alternatives are single-ester (Propionat 100, Enantat 250/400, Cypionat 250) or ester-free (Suspension 100). The blend delivers faster clinical onset than enanthate or cypionate without requiring the EOD injection schedule of Propionat 100. At 270 mg/mL it also concentrates more testosterone per milliliter than the 250 mg/mL single-ester products, reducing injection volume for the same weekly dose.
- Best scenario: users already experienced with Sustanon-style blends who want the same familiar formulation in Dragon Pharma's higher-concentration version; intermediate to advanced users who want cycle onset faster than enanthate provides without committing to every-other-day injections; 10–16 week mass or lean mass cycles where twice-weekly dosing is preferred; users building a first compound stack (e.g., Sustanon + Deca) on a testosterone base they are already managing; users who want to avoid a separate oral kickstart by using the propionate fraction for early onset
- Choose something else instead: users who prioritize clean, predictable pharmacokinetics for easier AI titration and PCT planning should use Enantat 250 — one ester, one defined half-life, simpler bloodwork interpretation; users on a first AAS cycle where managing estrogen is already the main challenge should not add the complexity of a multi-ester clearance curve; users running a short 6–8 week cycle should use Propionat 100 or Enantat 250 rather than Sustanon, because the decanoate tail extends total cycle duration beyond the intended window and delays PCT by 3 weeks
Sustanon 270 vs Alternatives
| Compound | Key Differences | Choose Sustanon 270 When | Choose Alternative When |
|---|---|---|---|
| Enantat 250 Dragon Pharma Testosterone Enanthate 250 mg/mL |
Single ester (enanthate, ~7–10 day half-life); fully predictable release curve; steady state in 3–4 weeks; simpler AI titration and PCT timing; 250 mg/mL vs 270 mg/mL; twice-weekly or once-weekly injections; no early propionate-driven peak | You want faster early cycle onset than enanthate provides without adding an oral kickstart, and you are comfortable with multi-ester PCT planning (21-day washout vs 14 days for enanthate) | Predictability matters more than onset speed; you are on a first cycle or optimizing bloodwork management; Enantat 250 has a defined half-life that makes every AI and PCT decision more straightforward |
| Enantat 400 Dragon Pharma Testosterone Enanthate 400 mg/mL |
Single ester (enanthate); 400 mg/mL concentration means less injection volume per dose; predictable release; no multi-ester complexity; higher concentration reduces PIP risk at the same dose volume as Sustanon 270; PCT at 14 days after last injection | The multi-ester early onset of Sustanon is the priority and you prefer the blend format for familiarity or a combination kickstart effect | You want maximum concentration per mL and single-ester pharmacokinetics; Enantat 400 provides more testosterone per mL than Sustanon 270 in the simplest possible ester format |
| Cypionat 250 Dragon Pharma Testosterone Cypionate 250 mg/mL |
Single ester (cypionate, ~8–12 day half-life); pharmacologically near-identical to enanthate; slightly longer half-life means once-weekly injections are workable; very stable blood levels; PCT at 14–18 days after last injection; 250 mg/mL | You prefer the blend profile with a fast-onset fraction rather than a flat single-ester rise | Stable, predictable hormone levels with convenient weekly injections are the priority; Cypionat 250 is a well-characterized single ester that many users find easier to manage over long cycles |
| Propionat 100 Dragon Pharma Testosterone Propionate 100 mg/mL |
Single ester (propionate, ~2–3 day half-life); EOD or every-3-day injections required; fast onset and fast clearance; PCT starts 3–5 days after last injection; significantly lower injection volume per dose at 100 mg/mL; more injection site management required | You want the multi-ester approach with just twice-weekly injections and the early onset of propionate without committing to EOD dosing | You need the fastest clearance window for competition, a short cycle, or frequent PCT cycling; Propionat 100's 3–5 day PCT entry vs Sustanon's 21 days is the decisive pharmacokinetic advantage for short protocols |
Combinations
| Goal | Stack | Notes |
|---|---|---|
| Classic mass cycle | Sustanon 270 540 mg/wk + Deca 300 400 mg/wk (14–16 weeks) + Dianabol 20 40 mg/day weeks 1–4 | The original "Sus + Deca + Dbol" mass stack; Sustanon provides the testosterone base with propionate-driven early onset; Deca 300 adds nandrolone's joint support and anabolic drive without additional aromatization; Dianabol 20 front-loads mass and glycogen in weeks 1–4; manage E2 with Arimidex DP throughout; include cabergoline 0.25 mg twice weekly for prolactin with nandrolone; HCG on-cycle for cycle lengths ≥ 12 weeks |
| Lean mass / recomp | Sustanon 270 270–540 mg/wk + Primobolan 100 400–600 mg/wk (12–14 weeks) | Lower estrogenic burden than the Sustanon + Deca stack; Primobolan 100 is non-17α-alkylated, mild on lipids, and provides lean anabolic output without aromatization; Sustanon drives the mass and strength component while Primobolan supports lean tissue retention; AI dose can often be reduced vs testosterone-only cycles because Primobolan contributes no estrogen; useful for athletes who want quality gains without the water retention of nandrolone stacks |
| Advanced strength and size | Sustanon 270 540 mg/wk + Trenbolone 100 300–400 mg/wk (10–12 weeks) | Trenbolone adds potent non-aromatizing anabolic and androgenic output; Sustanon provides the mandatory testosterone base and early onset; this stack is aggressive — experienced users only; Trenbolone suppresses E2 production indirectly, reducing AI requirements from the testosterone component; monitor BP weekly; do not use finasteride with trenbolone (worsens androgenic sides); no prolactin management needed with trenbolone acetate if using Trenbolone 100 |
| Contest prep base | Sustanon 270 270 mg/wk (base) + Masteron 100 400 mg/wk + Winstrol Inject 50 mg/day (final 8 weeks) | Sustanon at low dose maintains testosterone function and prevents low-E2 joint and libido issues while the dry stack produces hardness and density; Masteron 100 provides SHBG binding and mild anti-estrogenic activity; Winstrol Inject adds hardness and vascularity; the decanoate tail of Sustanon creates a 3-week clearance delay post-show — plan accordingly; monitor lipids aggressively with Winstrol in the stack (HDL suppression compounds) |
Side Effects & Management
| What May Occur | Background | How to Handle It |
|---|---|---|
| E2 elevation / gynecomastia | Testosterone aromatizes to estradiol via aromatase; supraphysiologic testosterone doses produce proportionally higher E2; the propionate fraction in Sustanon creates an early first-week E2 spike that can precede the AI reaching its steady-state effect; nipple sensitivity, water retention, and mood changes are the early warning signs; unmanaged E2 elevation is the primary cause of gynecomastia on testosterone cycles | Arimidex DP 0.5 mg EOD from day one; switch to Aromasin DP 12.5–25 mg EOD if estrogen rebound after Arimidex discontinuation is a concern; test E2 on a non-injection day at week 3 for a representative trough reading; adjust AI dose based on bloodwork, not symptoms alone — over-suppression (E2 < 15 pg/mL) causes joint pain, libido loss, and worsens lipid profile |
| Water retention and bloat | E2-driven intramuscular glycogen storage and extracellular fluid retention are the primary mechanisms; at doses above 400 mg/week water retention is expected and dose-dependent; the weight on the scale overstates lean mass gains proportionally; some water retention is physiologically normal and supports joint lubrication and training recovery | Maintain AI dosing in the therapeutic E2 range (20–40 pg/mL) — the single most effective intervention for testosterone-related water retention; dietary sodium reduction during the cycle; Ecosprin (Aspirin) 75 mg/day as baseline antiplatelet and cardiovascular support; severe estrogenic bloat indicates inadequate AI dose — recheck E2 before switching products |
| HDL suppression / lipid changes | Supraphysiologic testosterone suppresses HDL via hepatic lipase upregulation; the effect is amplified when Sustanon is stacked with DHT-derived compounds (Masteron, Winstrol) or oral AAS; LDL may rise modestly; lipid changes accumulate over the 10–16 week cycle duration typical for Sustanon-based protocols | Lipid panel at baseline and week 6–8; Rosulip (Rosuvastatin) 10–20 mg/day or Atorlip (Atorvastatin) 20–40 mg/day if HDL drops below 40 mg/dL or LDL exceeds 130 mg/dL; omega-3 supplementation throughout the cycle; reduce dietary saturated fat; HDL typically recovers within 6–8 weeks post-cycle |
| Blood pressure elevation | E2-driven fluid retention, progressively increasing hematocrit from EPO stimulation, and the cardiovascular load of intense training all contribute to BP elevation; on 12–16 week cycles the hematocrit component becomes increasingly significant as RBC mass accumulates; BP elevation is more pronounced when Sustanon is stacked with compounds that add to the cardiovascular load (Trenbolone, Dianabol) | Weekly home BP monitoring; target < 130/85 mmHg; first-line: optimize AI (reduce estrogenic fluid retention) and manage hematocrit; if BP persists above 140/90: Amlip (Amlodipine) 5 mg/day or Sartel (Telmisartan) 40 mg/day; Ecosprin 75 mg/day as ongoing antiplatelet support on cycles ≥ 12 weeks |
| Acne / oily skin / androgenic alopecia | DHT conversion via 5α-reductase elevates sebaceous gland activity and accelerates miniaturization of genetically susceptible scalp follicles; androgenic skin effects are dose-dependent and more pronounced at higher testosterone doses; the propionate fraction's early peak can trigger acne breakouts in the first 2 weeks before the cycle stabilizes | Moderate persistent acne: Doxycycline 100 mg/day; severe or cystic: Accutane Dragon Pharma; hair retention: Finasteride DP 1 mg/day + Minoxidil DP; note that finasteride only reduces DHT from testosterone — it does not modulate androgenicity from any non-testosterone compound co-administered in the stack |
| Libido disruption / ED | On-cycle libido disruption from testosterone is almost always E2-related rather than androgen deficiency; both extremes — E2 too high (from insufficient AI) and E2 too low (from over-suppression) — impair erectile function and sexual motivation; HPG suppression removes endogenous LH and FSH, which independently reduces intratesticular testosterone and can affect libido on very long cycles without HCG support | On-cycle: address E2 level first before adding ED medications; Proviron DP 25–50 mg/day raises free testosterone and supports libido; Cialis DP (Tadalafil) for ED once E2 is confirmed in range; HCG 5000 IU DP 250 IU twice weekly on cycles ≥ 12 weeks to maintain intratesticular testosterone and testicular volume |
| Testicular atrophy and HPG suppression | Exogenous testosterone suppresses LH and FSH via androgen-mediated negative feedback; testicular testosterone production stops and testicular volume decreases proportionally to the duration of suppression; on 12–16 week Sustanon cycles this is a consistent finding; the decanoate ester extends the suppression period by approximately 3 weeks beyond the last injection, making HCG support more relevant here than with shorter-ester protocols | HCG 250–500 IU twice weekly throughout cycles ≥ 10 weeks; this maintains testicular function and significantly improves the speed of HPG recovery during PCT; begin SERMs only after HCG pre-PCT blast if running HCG as a pre-PCT boost; see PCT section below for full protocol |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Hematocrit | Baseline (mandatory); week 6–8; end of cycle | Keep < 52%; above 54%: reduce dose, increase daily hydration to 3–4 L, consider therapeutic phlebotomy; on 14–16 week Sustanon cycles the EPO-mediated RBC accumulation is sustained and typically reaches its highest point near the end of the cycle |
| CBC (complete blood count) | Baseline; week 6–8 | RBC, WBC, and platelet counts within reference range; rising RBC trend confirms EPO stimulation — track absolute value against baseline, not just against lab reference range; any WBC elevation without infection warrants investigation before continuing the cycle |
| Lipid panel (HDL / LDL) | Baseline; week 6–8 | HDL > 40 mg/dL; LDL < 130 mg/dL; on 12–16 week testosterone cycles HDL suppression is consistent and cumulative — baseline value is essential for quantifying actual on-cycle change; lipids recover within 6–8 weeks post-cycle in most users |
| Estradiol (E2) | Week 3 (first AI adjustment point); mid-cycle if symptomatic | Target 20–40 pg/mL on sensitive assay; test on a non-injection day for a trough reading; the propionate fraction creates an early E2 spike in week 1 that settles as the decanoate component rises to steady state — week-3 is the earliest reliable AI calibration point once the full ester blend is active |
| Blood pressure | Baseline; weekly throughout cycle (home cuff) | < 130/85 mmHg; test at a consistent time (morning pre-injection is the most reproducible); readings consistently ≥ 140/90 on two separate days require intervention before continuing; BP tends to rise gradually through week 6–10 as hematocrit increases |
| LH + FSH | Baseline; mid-PCT (week 2–3); post-PCT (4–6 weeks after SERMs end) | Both < 1 IU/L expected on cycle — confirms suppression; recovery to > 3 IU/L by post-PCT check confirms functional HPG axis restart; if LH/FSH remain below 2 IU/L at PCT week 3, add Clomid DP to the protocol or extend SERM duration |
| Total testosterone | Baseline (mandatory pre-cycle); 4–6 weeks post-PCT completion | Documents natural pre-cycle baseline; post-PCT recovery target is within 10–15% of pre-cycle baseline; concurrent LH/FSH normalization confirms the axis is driving endogenous production rather than residual exogenous hormone from the decanoate tail |
PCT
The critical difference between Sustanon PCT and other testosterone PCT protocols is the decanoate ester. At a half-life of ~14–16 days, testosterone decanoate continues releasing hormone for 3+ weeks after the last injection. PCT cannot begin until blood testosterone drops toward baseline — which, accounting for the decanoate clearance, occurs approximately 21 days after the last Sustanon injection. Starting SERMs earlier while decanoate is still releasing testosterone means beginning HPG stimulation against ongoing suppression — an approach that does not work and wastes the SERM course.
| Phase | Protocol | Notes |
|---|---|---|
| PCT start timing | Begin SERMs 21 days after the last Sustanon injection | This is the defining timing difference vs Enantat 250 (14 days) or Propionat 100 (3–5 days); do not begin SERMs earlier based on subjective symptoms — the decanoate fraction continues suppressing LH/FSH while it is still releasing testosterone; if HCG pre-load is used, begin HCG 3–5 days after the last injection and start SERMs 4 days after the last HCG dose |
| HCG pre-load (cycles ≥ 10 weeks) | HCG 5000 IU Dragon Pharma 2,500 IU every 4 days × 2 doses, starting 3–5 days after the last injection; begin SERMs 4 days after the last HCG dose | Strongly recommended on cycles ≥ 10 weeks; maintains Leydig cell sensitivity during the decanoate clearance window and accelerates testicular recovery; do not run HCG concurrently with SERMs — HCG stimulates steroidogenesis via a non-HPG pathway that can partially counteract SERM signaling; for cycles ≥ 14 weeks consider on-cycle HCG (250–500 IU twice weekly) throughout |
| PCT weeks 1–4 (cycles ≤ 10 weeks) | Nolvadex DP 20 mg/day for 4 weeks; optionally add Clomid DP 50 mg/day for weeks 1–2 | Single SERM (Nolvadex) is adequate for cycles up to 10 weeks; Clomid is added if LH/FSH recovery is slow at the week-2 bloodwork check; dual SERM provides additive HPG stimulation through different receptor pathways |
| PCT weeks 1–6 (cycles ≥ 12 weeks) | Clomid DP 50/50/25/25 mg/day (weeks 1–4) + Nolvadex DP 20 mg/day (weeks 1–6) | Dual SERM for longer cycles or where prior cycles have produced sluggish HPG recovery; taper Clomid in weeks 3–4; continue Nolvadex alone through week 6; extended 6-week SERM course is appropriate for 14–16 week Sustanon cycles to account for the decanoate ester's extended suppression window |
| Post-PCT bloodwork | Total testosterone, LH, FSH — 4–6 weeks after stopping SERMs; recheck hematocrit | Testosterone should return to within 10–15% of pre-cycle baseline; LH and FSH > 3 IU/L confirms axis recovery; hematocrit typically normalizes within 6–8 weeks post-cycle; do not plan the next cycle until these markers are confirmed |
Practical Summary
- The decanoate ester changes every timing calculation — PCT starts 21 days after the last injection (not 14 like enanthate, not 3–5 like propionate); beginning SERMs earlier while decanoate is still releasing testosterone is the most common Sustanon PCT mistake; plan the full cycle-to-PCT timeline before the first injection
- Sustanon 270 packs 270 mg/mL — when converting from a 250 mg/mL Sustanon or Enantat 250 protocol, calculate the new injection volume first; 1 mL of Sustanon 270 delivers 270 mg, not 250; for a 500 mg/week target, that is 1.85 mL/week, not 2 mL
- Inject twice weekly (e.g., Monday and Thursday) rather than once weekly; once-weekly dosing allows the propionate fraction to clear between injections and creates a mid-week trough that produces noticeable energy and mood variability; twice weekly smooths the curve without increasing total dose
- AI management is bloodwork-guided, not symptom-guided — start Arimidex DP 0.5 mg EOD from day one and test E2 at week 3 when the full ester blend has reached active state; the early propionate peak produces a faster E2 rise than enanthate cycles, making the week-3 check more important here than on single-ester protocols
- HCG 250–500 IU twice weekly on-cycle is strongly recommended for cycles ≥ 12 weeks; the 3-week decanoate clearance period between the last injection and PCT entry is a window where testicular atrophy can worsen without HCG support; this is the longest such window of any Dragon Pharma single-product testosterone
- One vial (10 mL) = 2,700 mg; at 540 mg/week (2 mL/week) it lasts 5 weeks; at 270 mg/week (1 mL/week) it lasts 10 weeks; plan vial quantity before the cycle begins and account for the 21-day washout period that follows
Sustanon 270 Dragon Pharma remains one of the most recognized testosterone formats in performance use — a 4-ester blend that trades the pharmacokinetic simplicity of single-ester products for an earlier cycle onset that reduces the front-end waiting period characteristic of enanthate and cypionate. For users already comfortable with Sustanon-style protocols, the Dragon Pharma 270 mg/mL formulation delivers more testosterone per milliliter without changing the fundamental management framework. AI control, mid-cycle bloodwork, and a decanoate-aware PCT timeline are the consistent variables that determine outcomes on any Sustanon cycle. Steroid Warehouse stocks Sustanon 270 alongside Dragon Pharma's full cycle support lineup for complete in-cycle and post-cycle management.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial using 600 mg/week testosterone enanthate for 10 weeks, showing increased fat-free mass, muscle size, and strength, especially when combined with resistance training; foundational evidence for supraphysiologic androgen anabolic effects | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — synthetic testosterone-derived AAS pharmacology, androgen receptor mechanism, anabolic-androgenic effects, oral and injectable steroid classes, misuse patterns, monitoring, and adverse effect profile | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — testosterone and androgen derivative mechanisms of action, androgen receptor activity, HPG axis suppression, 5α-reduction, estradiol aromatization, synthetic androgen pharmacology, and androgen misuse context | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| Journal of Clinical Endocrinology & Metabolism / PubMed | Bhasin et al. 2018 — Endocrine Society clinical practice guideline for testosterone therapy in men with hypogonadism; useful for diagnostic standards, contraindications, monitoring, and separating medical TRT from non-medical supraphysiologic AAS use | Bhasin S, et al. (2018) ↗ |
| Circulation / PubMed | Baggish et al. 2017 — human study of cardiovascular toxicity associated with long-term illicit anabolic-androgenic steroid use; links chronic AAS exposure with myocardial dysfunction and accelerated coronary atherosclerosis | Baggish AL, et al. (2017) ↗ |
Please log in to write review.
-
I've used other brands before but Dragon Pharma was truly different, slightly higher dose at 270 vs 250 and I felt it way more than other domestic brands. I'd normally go to 500 but with this one I felt the same intensity at 400mg which is great for lower sides!
-
By far the best! Little to no side effects. Long life expectancy. Icc a week was perfect and always the foundation.
What is Sustanon 270?
Sustanon 270 is an injectable testosterone blend for muscle growth; see What is Sustanon 270. It's versatile—consult professionals for safe use.
How often to inject Sustanon 270?
Inject every 3-7 days, typically weekly or twice weekly; see How to Use. Use with labs—consult for tailored plans.
Is there anything stronger than Sustanon 270?
Compounds like Trenbolone or Methyltrienolone may be stronger but riskier; see Is There Anything Stronger Than Sustanon 270. Consult professionals for alternatives.
How does Sustanon 270 work?
It binds androgen receptors for muscle and strength gains; see Mechanism of Action. It delivers sustained results—monitor with labs.
Is Sustanon 270 safe?
It's safe with proper dosing and monitoring; see Side Effects. Manage risks with ancillaries—consult professionals for safety.
How long does it take to notice effects from Sustanon 270?
Because it contains both short and long esters, users often report early improvements in training performance and recovery, while muscle growth and strength gains continue to develop over several weeks.
What are the main benefits of Sustanon 270?
Commonly reported benefits include increased muscle mass, enhanced strength, improved recovery, better workout performance, and support for lean muscle development.
What makes Sustanon 270 different from single-ester testosterone products?
Sustanon 270 combines multiple testosterone esters in one formulation, providing both faster initial activity and prolonged release compared to products that contain only a single ester.
Related Products
Lab Tested
Anavar 10 Dragon Pharma
Oxandrolone 10 mg · DHT-derived oral AAS · non-aromatizing
Class
DHT-Derived
Oral AAS
Form / Active Life
No ester
~9 hours · dose twice daily
Aromatization
None
No estrogen conversion
User Level
Beginner
to Advanced
Typical Dose
40–80 mg
per day (men)
Frequency
N/A (oral)
twice daily, with meals
Cycle Length
6–8 weeks
typical range
Available Domestic
Best Seller
Lab Tested
Cialis DP Dragon Pharma
Tadalafil 20 mg · PDE5 inhibitor · up to 36-hour duration
Category
PDE5 Inhibitor
Erectile dysfunction
Form / Strength
Oral tablet
20 mg per tab
Context
ED / sexual function
on-demand or daily protocol
Monitoring
Blood pressure
if on antihypertensives
Typical Dose
10–20 mg
on-demand · or 5 mg/day
Onset
30–45 min
unaffected by food
Duration
Up to 36 h
per dose
Available Domestic
Lab Tested
Cut Mix 150 Dragon Pharma
Test P 50 · Tren A 50 · Masteron P 50 · 150 mg/ml
Category
Injectable AAS Blend
3-compound / short esters
Composition
150 mg/ml total
Test P · Tren A · Drost P
Context
Cutting · Recomp
lean mass · fat loss · density
Administration
IM injection
every other day (EOD)
Typical Dose
1–1.5 ml EOD
~525–787 mg/week
Frequency
EOD
short ester schedule
Cycle Length
8–10 weeks
PCT 3–4 days after last inj
Available Domestic
Best Seller
Lab Tested
Cypionat 250 Dragon Pharma
Testosterone Cypionate · 250 mg/ml · Long-ester injectable
Class
Anabolic Steroid
injectable testosterone ester
Half-life
~8 days
twice-weekly injection
Context
Bulking · TRT
mass, strength, hormone base
Administration
IM injection
glute, quad, or delt
Typical Dose
250–500 mg/wk
1–2 ml per week
Frequency
2× per week
Mon / Thu split
Cycle Length
12–16 weeks
PCT required after
Available Domestic
Best Seller
Lab Tested
Deca-300 Dragon Pharma
Nandrolone Decanoate · 300 mg/ml
Class
Anabolic Steroid
19-nor testosterone derivative
Half-life
~15 days
decanoate ester, weekly dosing
Context
Bulking · Joints
mass, collagen, recovery
Administration
IM injection
weekly or E5D
Typical Dose
300–600 mg/wk
always with testosterone base
Frequency
Weekly / E5D
stable long-ester levels
Cycle Length
12–16 weeks
PCT 3 weeks after last pin
Available Domestic
Lab Tested
Deca-500 Dragon Pharma
Nandrolone Decanoate · 500 mg/ml
Class
Anabolic Steroid
19-nor testosterone derivative
Half-life
~15 days
decanoate ester, weekly dosing
Context
Bulking · Joints
high-dose, low injection volume
Administration
IM injection
weekly or E5D
Typical Dose
400–600 mg/wk
always with testosterone base
Frequency
Weekly / E5D
stable long-ester levels
Cycle Length
12–16 weeks
PCT 3 weeks after last pin
Available Domestic
Best Seller
Lab Tested
Enantat 250 Dragon Pharma
Testosterone Enanthate 250 mg/mL · Long-Ester Injectable · high aromatization
Class
Androgenic-Anabolic
Testosterone / Enanthate ester
Ester / Active Life
Enanthate (C8)
~4.5 day t½ · 8–10 days active
Aromatization
High
AI required from day 1
User Level
Beginner
to Advanced
Typical Dose
250–750 mg
per week
Injection Frequency
E7D or E3.5D
once or twice weekly
Cycle Length
10–16 weeks
PCT 14 days after last pin
Available Domestic
Lab Tested
EQ 300 Dragon Pharma
Boldenone Undecylenate 300 mg/mL · long-ester injectable · requires testosterone base
Class
Testosterone Derivative
Injectable AAS
Ester / Active Life
Undecylenate (C11)
~14-day active half-life
Aromatization
Low to Moderate
~50% of testosterone per mg
User Level
Intermediate
to Advanced
Typical Dose
300–600 mg
per week
Injection Frequency
E3.5D or E7D
twice or once weekly
Cycle Length
12–16 weeks
PCT 21 days after last pin